Chromocell to Present at Upcoming Fall Investor Conferences

FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) — Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel II, CEO, will present at the upcoming LDMicro and Spartan Capital investor conferences.

Details for the conferences and presentations are as follows:

LDMicro Main Event XVII (October 28-30, 2024)

Presentation: October 29, 2024
Time: 10:00 AM – 10:25 AM PT
Location: Luxe Sunset BLVD Hotel, Los Angeles
In-person registration: LINK
Virtual attendance: LINK
Available for 1×1 meetings: October 29th

The Main Event has become the industry standard for anyone who is involved in the micro-cap world. Come join us as we showcase the next “big” names in our space. LD Micro Main Event XVII (October 29th & 30th)

Spartan Capital Investor Conference 2024 (November 4, 2024)

Presentation: November 4, 2024
Time: 9:45 AM – 10:00 AM ET
Location: The Pierre Hotel, NYC
Register for In-person attendance: LINK
Available for 1×1 meetings.

The Spartan Capital Investor Conference is a premier event that brings together public company executive teams, institutional investors, thought leaders in the U.S. capital markets, and representatives from Spartan Capital. This conference offers a unique opportunity for networking, knowledge sharing, and strategic discussions. The conference attracts a distinguished audience, including executive teams from public companies, institutional investors, thought leaders in the U.S. capital markets, Spartan Capital representatives.

About Chromocell

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the amount of shares of Common Stock to be repurchased under the Repurchase Plan, if any, (ii) the Company’s belief that the trading price of its Common Stock does not reflect its clinical progress, (iii) the Company’s plans and ability to successfully develop and commercialize compounds, (iv) the Company’s belief that its portfolio of therapeutics will be suitable for neuropathic and chronic pain, (v) the Company’s plan and ability to successfully develop its intellectual properly independently or with partners, (vi) the Company’s ability to conduct repurchases in accordance with applicable laws and regulations, (vii) our ability to enhance stockholder value and (viii) the impact of laws and regulations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.

Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to (i) the Company expending its limited resources to pursue a compound or indication and failing to capitalize on different compounds or indications that may be more profitable or for which there is a greater likelihood of success and the Company potentially not being successful in discovering, developing and commercializing additional compounds, (ii) the Company needing to establish its market development capabilities to commercialize its products with the failure to do so potentially resulting in an inability to generate any revenue, (iii) there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s clinical progress, and (iv) the Company’s ability to successfully develop its intellectual property and portfolio. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
[email protected]

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow